VeraDermics Inc.
Veradermics is a biopharmaceutical company focused on advancing first-in-class therapeutics that address common dermatologic and aesthetic conditions. The company aims to disrupt the dermatology landscape by developing innovative solutions for underserved markets, improving treatment outcomes, and establishing new industry standards. Led by a team of dermatologists and industry experts, Veradermics leverages clinical experience to identify and develop novel drugs targeting conditions such as alopecia, warts, molluscum contagiosum, and atopic dermatitis.
Industries
Nr. of Employees
small (1-50)
VeraDermics Inc.
Products
Non-hormonal oral therapy for pattern hair loss (VDPHL01)
Investigational, non-hormonal oral small-molecule therapeutic in clinical development for androgenetic alopecia/pattern hair loss.
Dissolvable microarray immunotherapy patch for common warts (VDMN)
Investigational dissolvable microarray patch delivering an antigen extract to stimulate local immune clearance of common warts without injection.
Topical immunotherapy for alopecia areata (VDAA)
Topical, contact immunotherapy candidate intended for monthly application to treat all severities of alopecia areata.
Topical antiviral candidate for molluscum contagiosum (VDMC-7269)
Preclinical/new chemical entity topical antiviral designed to inhibit poxvirus replication with limited systemic absorption, advanced via an academic license.
Oral immunomodulator for atopic dermatitis (VDAD)
Preclinical oral new chemical entity intended to modulate immune response for treatment of atopic dermatitis.
Non-hormonal oral therapy for pattern hair loss (VDPHL01)
Investigational, non-hormonal oral small-molecule therapeutic in clinical development for androgenetic alopecia/pattern hair loss.
Dissolvable microarray immunotherapy patch for common warts (VDMN)
Investigational dissolvable microarray patch delivering an antigen extract to stimulate local immune clearance of common warts without injection.
Topical immunotherapy for alopecia areata (VDAA)
Topical, contact immunotherapy candidate intended for monthly application to treat all severities of alopecia areata.
Topical antiviral candidate for molluscum contagiosum (VDMC-7269)
Preclinical/new chemical entity topical antiviral designed to inhibit poxvirus replication with limited systemic absorption, advanced via an academic license.
Oral immunomodulator for atopic dermatitis (VDAD)
Preclinical oral new chemical entity intended to modulate immune response for treatment of atopic dermatitis.
Services
Business development and licensing
Engagements to discuss licensing, product development partnerships, and strategic alliances for dermatology therapeutics.
Business development and licensing
Engagements to discuss licensing, product development partnerships, and strategic alliances for dermatology therapeutics.
Expertise Areas
- Clinical trial management (Phase 1–3, multicenter)
- Dermatology drug development
- Transdermal delivery and microarray platform development
- Antiviral discovery and topical drug development
Key Technologies
- Dissolvable microarray transdermal patch
- Topical antiviral small molecules
- Oral small-molecule therapeutics
- Antigen-based immunotherapy formulations